Translation and cross-cultural adaptation to Brazilian Portuguese of two brief screening tools for at-risk psychosis youth: the Prodromal Questionnaire (PQ-16) and the PRIME-Screen
- PMID: 34551241
- PMCID: PMC10164406
- DOI: 10.47626/2237-6089-2021-0276
Translation and cross-cultural adaptation to Brazilian Portuguese of two brief screening tools for at-risk psychosis youth: the Prodromal Questionnaire (PQ-16) and the PRIME-Screen
Abstract
Introduction: Prodromal characteristics of psychosis have been described for more than a century. Over the last three decades, a variety of studies have proposed methods to prospectively identify individuals (and youth in particular) who are at high risk of developing a psychotic disorder. These studies have validated various screening instruments and made them available in several languages. Here, we describe the translation into Brazilian Portuguese and cross-cultural adaptation of two such screening tools - the Prodromal Questionnaire-16 (PQ-16) and the Prevention through Risk Identification, Management, and Education (PRIME)-Screen.
Method: Two bilingual native speakers of Brazilian Portuguese translated the questionnaires from English. A native English speaker then performed back-translations into English. These back-translated versions were submitted to the original authors. They provided feedback and later approved the final versions.
Results: After translation and cross-cultural adaptation, no items needed to be changed in the adapted PQ-16 and four items were revised in the PRIME-Screen. After the peer-review process, we included two suggestions in the PQ-16 to facilitate use of the tool in our cultural and social contexts. The PRIME-Screen did not need further changes.
Conclusion: These new instruments can help screen Brazilian Portuguese-speaking patients who are at risk of psychosis in primary care.
Keywords: Psychosis; at-risk mental states; screening tools; ultra-high risk.
Conflict of interest statement
Ary Gadelha has been a consultant and/or advisor to or has received honoraria from Aché, Daiichi-Sankyo, Torrent, Bayer, Cristalia, and Janssen. Rodrigo Affonseca Bressan has received research grants from Eli-Lilly, Lundbeck, Novartis, Roche, and Janssen; has been a shareholder in Biomolecular Technology Ltd.; and has received speaking fees from AstraZeneca, Bristol, EliLilly, Lundbeck, Janssen, Aché, and Torrent. Pedro Mario Pan has received personal fees from Sandoz, Daiichi Sankyo, Eurofarma, and Abbott. No other conflicts of interest are declared concerning publication of this article.
Figures



References
-
- Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64:19–28. - PubMed
-
- Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:655–679. - PubMed
-
- Mathers C, Ma Fat D, Boerma T. World Health Organization (WHO) The global burden of disease: 2004 update. Genebra: WHO; 2004.
-
- Jeppesen P, Petersen L, Thorup A, Abel MB, Øhlenschlaeger J, Christensen TØ, et al. The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychol Med. 2008;38:1157–1166. - PubMed
-
- Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull. 1996;22:283–303. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical